Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2014-03-14 Regulatory Filings
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
F-1/A
Regulatory Filings Classification · 95% confidence The document is an Amendment No. 1 to Form F-1 filed with the SEC, which is a Registration Statement under the Securities Act of 1933. It is related to an initial public offering (IPO) of Bio Blast Pharma Ltd. The text includes detailed information typical of a prospectus for an IPO, such as risk factors, use of proceeds, dividend policy, capitalization, dilution, selected financial data, management discussion and analysis, business description, management, principal shareholders, share capital description, underwriting, legal matters, and financial statements. This type of filing is a registration statement for securities offering, which is not explicitly listed in the provided categories. However, the closest and most appropriate category for this document is Regulatory Filings (RNS), as it covers general regulatory announcements and filings that do not fit into other specific categories. The document is not an Annual Report, Earnings Release, or any other specific report type but a registration statement amendment for an IPO.
2014-03-14 English
Regulatory Filings 2014
Regulatory Filings
2014-03-06 English
Regulatory Filings 2014
Regulatory Filings
2014-02-13 English
F-1
Capital/Financing Update Classification · 95% confidence The document is a Form F-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC). It is a registration statement under the Securities Act of 1933 for Bio Blast Pharma Ltd. The document includes details about the proposed initial public offering (IPO), including the offering price, underwriting details, risk factors, business overview, management discussion, and financial data. The Form F-1 is used for registration of securities for public offering and is not a financial report like an annual or quarterly report, nor is it a call transcript, audit report, or other categories listed. It is a capital markets filing related to the company's financing and capital raising activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or notice, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2014-02-07 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.